Loading...

PE anti-mouse NK-1.1 Antibody

Pricing & Availability
Clone
PK136 (See other available formats)
Regulatory Status
RUO
Other Names
NKR-P1C, NKR-P1B, Ly-55, CD161, CD161b, CD161c
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
PK136_PE_NK-11_Antibody_051018
C57BL/6 mouse splenocytes were stained with CD49b (DX5) APC and NK1.1 (clone PK136) PE (left) or mouse IgG2a, κ PE isotype control (right).
  • PK136_PE_NK-11_Antibody_051018
    C57BL/6 mouse splenocytes were stained with CD49b (DX5) APC and NK1.1 (clone PK136) PE (left) or mouse IgG2a, κ PE isotype control (right).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
108707 50 µg 49€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108708 200 µg 144€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
NK-1+ cells from mouse spleen and bone marrow
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, complement-dependent cytotoxicity3, in vivo depletion4,5,9,10, mediation of in vitro redirected lysis6, blocking of NK cell function7, induction of proliferation8, immunohistochemical staining of frozen sections11, immunofluorescence microscopy11, and spatial biology (IBEX)16,17. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 108712).

Application References

(PubMed link indicates BioLegend citation)
  1. Carlyle JR, et al. 1999. J. Immunol. 162:5917. (IP)
  2. Sentman CL, et al. 1989. Hybridoma 8:605. (IP)
  3. Koo GC, et al. 1984. Hybridoma 3:301. (Cyt)
  4. Sentman CL, et al. 1989. J. Immunol. 142:1847. (Deplete)
  5. Koo GC, et al. 1986. J. Immunol. 137:3742. (Deplete)
  6. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  7. Kung SK, et al. 1999. J. Immunol. 162:5876. (Block)
  8. Reichlin A, et al. 1998. Immunol. Cell Biol. 76:143.
  9. Drobyski W, et al. 1996. Blood 87:5355. (Deplete)
  10. Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (Deplete)
  11. Kanwar JR, et al. 2001. J. Natl. Cancer Inst. 93:1541. (IHC, IF)
  12. Kroemer A, et al. 2008. J. Immunol. 180:7818. PubMed
  13. Kim JY, et al. 2009. Exp Mol Med. 30:288. PubMed
  14. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  15. Lee H, et al. 2014. Invest Ophthalmol Vis Sci. 55:2885. PubMed
  16. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  17. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Sade-Feldman M,et al. 2017. Nat Commun.. 10.1038/s41467-017-01062-w. PubMed
  2. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  3. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  4. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  5. Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed
  6. Calabrese DR, et al. 2020. J Clin Invest. . PubMed
  7. Valencia–Hernandez AM, et al. 2020. Cell Host & Microbe. 27(6):950-962. PubMed
  8. John S, et al. 2020. Sci Rep. 10:11377. PubMed
  9. Zhang R, et al. 2019. Cell Rep. 28:2647. PubMed
  10. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  11. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  12. Lee S, et al. 2021. JCI Insight. 6:. PubMed
  13. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  14. Lee Y, et al. 2020. J Innate Immun. 1:. PubMed
  15. Israelow B, et al. 2020. bioRxiv. . PubMed
  16. Gonalves S, et al. 2021. Cell Reports. 34(11):108860. PubMed
  17. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  18. Zheng M, et al. 2016. Sci Rep. 6:28729. PubMed
  19. Engel O, et al. 2015. Stroke. 46: 3232 - 3240. PubMed
  20. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  21. Adomati T, et al. 2020. Cell Reports. 30(11):3671-3681. PubMed
  22. Hsieh M, et al. 2006. J Immunol. 177:1855. PubMed
  23. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  24. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  25. Lee AK, et al. 2020. Radiat Res. 193:305. PubMed
  26. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  27. Böttcher JP, et al. 2018. Cell. 172:1022. PubMed
  28. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  29. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  30. Liu X, et al. 2020. Nature. . PubMed
  31. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  32. Nakagawa S et al. 2017. Cell host & microbe. 22(5):667-677 . PubMed
  33. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  34. Astrakhan A, et al. 2009. J Immunol. 182:7370. PubMed
  35. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  36. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  37. Shibata K, et al. 2014. J Immunol. 192:2210. PubMed
  38. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  39. Shemer A, et al. 2020. Immunity. 53(5):1033-1049.e7. PubMed
  40. Dai B, et al. 2022. Theranostics. 12:7603. PubMed
  41. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  42. Wang LT, et al. 2021. STAR Protocols. 2(1):100337. PubMed
  43. Marsh S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1316 - 1325. PubMed
  44. Spees A, et al. 2014. Infect Immun . 82:1692. PubMed
  45. Chen Y, et al. 2012. PLoS One. 7:e47190. PubMed
  46. Li J, et al. 2019. JCI Insight. 5. PubMed
  47. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  48. Devalaraja S, et al. 2020. STAR Protoc. 1:100188. PubMed
  49. Martens CR, et al. 2022. PLoS Pathog. 18:e1010342. PubMed
  50. Zhou Y, et al. 2022. Nat Commun. 13:2906. PubMed
  51. Lee M, et al. 2014. PLoS One. 9:112666. PubMed
  52. Hiramoto T, et al. 2018. Mol Ther. 26:1255. PubMed
  53. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  54. Ruf B, et al. 2021. Cancer Immunol Res. 9:1024. PubMed
  55. McAlpine CS, et al. 2021. Nature. 595:701. PubMed
  56. Qiu Z, et al. 2016. Sci Rep. 6:31936. PubMed
  57. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  58. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  59. Hulsmans M et al. 2017. Cell. 169(3):510-522 . PubMed
  60. Galvani E, et al. 2020. Nat Commun. 11:853. PubMed
  61. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  62. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  63. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  64. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  65. Markman JL, et al. 2020. Nat Commun. 11:1613. PubMed
  66. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  67. Tang X, et al. 2022. Cell Rep. 41:111673. PubMed
  68. Garland KM, et al. 2021. Front Immunol. 12:753472. PubMed
  69. Huang B, et al. 2015. PLoS One. 10: 0134715. PubMed
  70. Kim DH, et al. 2018. Nat Commun. 9:503. PubMed
  71. Li Z, et al. 2018. Front Immunol. 9:347. PubMed
  72. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  73. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
  74. Duan B, et al. 2010. J Immunol. 185:335. PubMed
  75. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  76. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  77. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  78. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  79. Kadowaki T, et al. 2012. Clin Immunol. 142:296. PubMed
  80. Olson M, et al. 2014. J Immunol. 193:5420. PubMed
  81. Choi EW, et al. 2020. Sci Rep. 10:12001. PubMed
  82. Bachu M, et al. 2019. J Biol Chem. 294:1904. PubMed
  83. Wu S, et al. 2022. BMC Immunol. 23:17. PubMed
  84. Lang V, et al. 2021. Elife. 10:. PubMed
  85. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  86. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  87. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  88. Korrer M, Routes J 2014. PLoS One. 9:91370. PubMed
  89. Nowlan B, et al. 2019. Haematologica. 105:71. PubMed
  90. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  91. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  92. Gamrekelashvili J, et al. 2021. Bio Protoc. 11:e4007. PubMed
  93. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  94. Yang C, et al. 2016. Sci Rep. 6:34643. PubMed
  95. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  96. Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
  97. Hohsfield LA, et al. 2020. J Neuroinflammation. 0.902083333. PubMed
  98. Vasamsetti SB, et al. 2018. Immunity. 49:93. PubMed
  99. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  100. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
  101. Desai P, et al. 2021. Cell. 184(5):1214-1231.e16. PubMed
  102. Wang LT, et al. 2020. Cell Rep. 32:108188. PubMed
  103. Lokken K, et al. 2014. PLoS Pathog. 10:1004049. PubMed
  104. Ovadya Y, et al. 2018. Nat Commun. 9:5435. PubMed
  105. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  106. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  107. He B, et al. 2020. Cell Reports. 30(3):714-724.e5.. PubMed
  108. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  109. Okamoto T, et al. 2011. Biomaterials. 32:4925. PubMed
  110. Kitur K, et al. 2015. PLoS Pathog. 11:1004820. PubMed
  111. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  112. Salazar V, et al. 2019. Cell Rep. 26:1585. PubMed
  113. Namkoong H, et al. 2018. PLoS Pathog. 14:e1006955. PubMed
  114. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  115. Rustenhoven J, et al. 2021. Cell. 184(4):1000-1016.e27. PubMed
  116. Israelow B, et al. 2020. J Exp Med. 217:00:00. PubMed
  117. Baglaenko Y, et al. 2016. PLoS One. 11: 0150515. PubMed
  118. Hendrikx S et al. 2019. Cell reports. 26(5):1227-1241 . PubMed
  119. Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed
  120. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  121. Tähtinen S, et al. 2022. Nat Immunol. 23:532. PubMed
  122. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  123. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  124. Orr MT, et al. 2019. NPJ Vaccines. 4:1. PubMed
  125. Sartorius R, et al. 2018. Front Immunol. 1.413888889. PubMed
  126. Zhou X, et al. 2021. Nutr Metab (Lond). 18:64. PubMed
  127. Wu C, et al. 2018. Scand J Immunol. 87:e12661. PubMed
  128. Hohsfield LA, et al. 2021. Elife. 10:. PubMed
  129. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
  130. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  131. Han J, et al. 2015. Cancer Res . 75: 5273 - 5282. PubMed
  132. Dienz O, et al. 2009. J Exp Med. 206:69. PubMed
RRID
AB_313394 (BioLegend Cat. No. 108707)
AB_313395 (BioLegend Cat. No. 108708)

Antigen Details

Structure
NKR-P1 gene family
Distribution

NK and NK-T cells in the NK1.1 mouse strains (C57BL, FVB/N, NZB)

Function
NK cell activation, IFN-γ production, cytotoxic granule release
Cell Type
NK cells, NKT cells
Biology Area
Immunology, Innate Immunity
Antigen References

1. Lanier LL. 1997. Immunity 6:371.
2. Yokoyama WM, et al. 1993. Ann. Rev. Immunol. 11:613.
3. Koo GC, et al. 1986. J. Immunol. 137:3742.
4. Giorda R, et al. 1991. J. Immunol. 147:1701.

Gene ID
17059 View all products for this Gene ID
UniProt
View information about NK-1.1 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All NK-1.1 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse NK-1.1 PK136 FC
Biotin anti-mouse NK-1.1 PK136 FC
FITC anti-mouse NK-1.1 PK136 FC
PE anti-mouse NK-1.1 PK136 FC
Purified anti-mouse NK-1.1 PK136 FC,CyTOF®,IP,Depletion,Block,IHC-F
PE/Cyanine7 anti-mouse NK-1.1 PK136 FC
PE/Cyanine5 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 488 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 647 anti-mouse NK-1.1 PK136 FC
Pacific Blue™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 711™ anti-mouse NK-1.1 PK136 FC
APC/Cyanine7 anti-mouse NK-1.1 PK136 FC
PerCP anti-mouse NK-1.1 PK136 FC
PerCP/Cyanine5.5 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 700 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 421™ anti-mouse NK-1.1 PK136 FC,SB
Brilliant Violet 570™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 650™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 510™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 605™ anti-mouse NK-1.1 PK136 FC
Purified anti-mouse NK-1.1 (Maxpar® Ready) PK136 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 785™ anti-mouse NK-1.1 PK136 FC
APC/Fire™ 750 anti-mouse NK-1.1 PK136 FC
TotalSeq™-A0118 anti-mouse NK-1.1 PK136 PG
Ultra-LEAF™ Purified anti-mouse NK-1.1 PK136 FC,CyTOF®,IP,Depletion,Block,IHC-F
TotalSeq™-B0118 anti-mouse NK-1.1 PK136 PG
TotalSeq™-C0118 anti-mouse NK-1.1 PK136 PG
PE/Fire™ 810 anti-mouse NK-1.1 PK136 FC
PE/Fire™ 640 anti-mouse NK-1.1 PK136 FC
Spark UV™ 387 anti-mouse NK-1.1 PK136 FC
PE/Fire™ 700 anti-mouse NK-1.1 PK136 FC
Go To Top Version: 3    Revision Date: 05/10/2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account